Insider’s View: Deciphering Corvus Pharmaceuticals Inc (CRVS)’s Financial Health Through Ratios

Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.

In other words, the price has increased by $0.00 from its previous closing price. On the day, 0.76 million shares were traded.

Ratios:

We take a closer look at CRVS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on January 02, 2025, initiated with a Buy rating and assigned the stock a target price of $11.

On August 18, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $7.

Stock Price History:

Over the past 52 weeks, CRVS has reached a high of $10.00, while it has fallen to a 52-week low of $1.75. The 50-Day Moving Average of the stock is 12.41%, while the 200-Day Moving Average is calculated to be -26.32%.

Shares Statistics:

A total of 68.17M shares are outstanding, with a floating share count of 53.34M. Insiders hold about 30.83% of the company’s shares, while institutions hold 29.56% stake in the company.

Leave a Reply

Your email address will not be published. Required fields are marked *

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.